Consensus on Glycemic Management for Patients With Coronary Heart Disease and Type 2 Diabetes
The prevalence of patients with coronary heart disease and diabetes mellitus is notably high,posing significant residual cardiovascular risks even after routine medication interventions such as antihypertensive,lipid-lowering,and antithrombotic treatments.Recent studies have demonstrated that some glucose-lowering medications have cardiovascular benefits for patients with type 2 diabetes.However,a survey indicates that cardiologists may not be fully acquainted with the optimal screening timing,indicators and diagnostic criteria of type 2 diabetes,and their knowledge and prescription of novel glucose-lowering medications with cardiovascular benefits demonstrated in dedicated cardiovascular outcomes trials,such as glucagon like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors,are generally less.In this context,based on domestic and international guidelines as well as consensus and the latest evidence-based evidence,this consensus aims to standardize the glycemic management for patients with acute coronary syndrome,chronic coronary syndrome,and perioperative management for percutaneous coronary intervention.It highlights the key points in type 2 diabetes screening and diagnostic,and comprehensive management of cardiovascular risk for patients with coronary heart disease.The consensus elaborates on the principles and algorithms of glycemic management for coronary heart disease patients,without involving acute complications of diabetes,clarifies the clinical practice of glucose-lowering medications with cardiovascular benefits,and promotes the standardized use of the above medications in cardiovascular and other related specialty fields.Additionally,it addresses the non-glucose-lowering treatment to comprehensively reduce cardiovascular risks.
NETL
NSTL
万方数据
